The Food And Drug Administration (FDA) approved an emergency use authorization for the Pfizer-BioNTech vaccine for children as young as 5 years old despite the fact that its Pfizer-connected advisory committee knew about numerous adverse events that were reported in Pfizer’s clinical trials for children, including adverse events that were determined to be “related” to the clinical vaccine trial. The Briefing Packet for the FDA advisory committee meeting shows that the FDA advisers used clinical studies sponsored by BioNTech and conducted by or supported by Pfizer to approve the vaccine for young children. Talk about a conflict of interest! NATIONAL FILE reported on the FDA advisory committee’s massive Pfizer connections and how committee members have worked for Pfizer and are making money from the Pfizer vaccine. So what kind of adverse events were discovered in the clinical trials for children? The advisory committee meeting briefing packet, published by the FDA, shows that clinical trials found “related” illnesses including Lymphadenopathy, arthralgia, paresthesia, nervous tic, hematochezia (characterized by bloody stool, which sent the participant to the “emergency department”) pyrexia (fever), neutropenia (low white blood cell count), hypersensitivity reaction, angioedema, and rashes. Meanwhile, a case of the blood vessel disorder Henoch-Schoenlein purpura was reported but was conveniently classified as “non related” to the vaccine experiment.
Here is the “Vaccines and Related Biological Products Advisory Committee Meeting October 26, 2021 Briefing Document” published by the FDA. Page 15 lists an “OVERVIEW OF CLINICAL STUDIES.” Two clinical studies are listed. The first clinical study listed is “Phase 1/2/3 Registrational Study C4591001,” which was sponsored by BioNTech and conducted by Pfizer. The other clinical study listed is “Phase 1/2/3 Pediatric Study C4591007,” which is listed as being sponsored by BioNTech and supported by Pfizer. “Pediatric Study c4591007” is an ongoing study and it was used by the FDA for approval of the vaccine for ages 5 to 12. That’s right. The FDA meeting’s data was taken from an ongoing study conducted by the very makers of the vaccine. The information below comes from the FDA Briefing Packet’s review of Pfizer Pediatric Study C4591007.